Guinness Asset Management LTD Buys 3,788 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Guinness Asset Management LTD increased its stake in Thermo Fisher Scientific by 5.3% during the first quarter, owning a total of 75,551 shares worth approximately $37.6 million.
• Multiple institutional investors, including Mondrian Investment Partners LTD with a 146.1% increase, have also boosted their holdings in Thermo Fisher Scientific.
• Thermo Fisher Scientific recently reported quarterly earnings of $5.36 per share, above estimates, and announced a quarterly dividend of $0.43 per share to be paid on October 15th.

Guinness Asset Management LTD raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,551 shares of the medical research company's stock after acquiring an additional 3,788 shares during the period. Guinness Asset Management LTD's holdings in Thermo Fisher Scientific were worth $37,596,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. 1248 Management LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $173,000. Osterweis Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 20.5% during the first quarter. Osterweis Capital Management Inc. now owns 77,455 shares of the medical research company's stock worth $38,542,000 after purchasing an additional 13,169 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Modern Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 7.4% during the first quarter. Modern Wealth Management LLC now owns 6,074 shares of the medical research company's stock worth $3,023,000 after purchasing an additional 420 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of Thermo Fisher Scientific by 19.6% during the first quarter. Jones Financial Companies Lllp now owns 103,983 shares of the medical research company's stock worth $51,920,000 after purchasing an additional 17,068 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 2.4%

TMO traded down $11.93 during trading on Friday, hitting $479.48. The company's stock had a trading volume of 1,543,232 shares, compared to its average volume of 1,509,627. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock's fifty day moving average price is $466.86 and its 200-day moving average price is $450.58. The firm has a market capitalization of $181.06 billion, a P/E ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the firm earned $5.37 earnings per share. The company's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Seventeen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.